High concentration formulations of anti-CSF1 and anti-CSF1R antibodies

Inventors

Alani, Laman • Hsu, Chung-Chiang • Zhu, Aihua • Johnson, Kirk William • Huang, Michael

Assignees

AmMax Bio Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-11419822-B2

Patent

Publication Date

2022-08-23

Expiration Date


Abstract

Provided are high concentration stable formulations of anti-CSF1R/CSF1 antibodies. An example formulation includes 105 to 250 mg/mL of the antibody, 100 mM to 200 mM of arginine glutamate or arginine HCl, 10 mM to 50 mM histidine, and 0.015 to 0.035 w/v % of polysorbate 80, at a pH of 5.4 to 5.6. Also provided are methods of using the formulations for treating diseases.

Core Innovation

The invention relates to stable high-concentration aqueous pharmaceutical compositions comprising 105 to 250 mg/mL of an antibody in an acidic pH range. The antibody comprises a heavy chain with the amino acid sequence of SEQ ID NO:7 and a light chain with the amino acid sequence of SEQ ID NO:8. The composition includes a salt of arginine selected from arginine glutamate, arginine aspartate, and arginine HCl, histidine, and polysorbate selected from PS 80 and PS 20, at a pH of 5.4-5.6.

The disclosed problem is that high concentration antibody formulations face challenges including viscosity, protein-protein interactions, aggregation and isotonicity concerns, together with turbidity/opalescence, protein aggregation, phase separation, and deamidation. The disclosure identifies that formulation at a narrow acidic pH window is important for maintaining stability at high concentration. It further identifies histidine and arginine salts as key components for low viscosity and favorable stability in the stated pH range.

The invention also includes lyophilized solid versions derived from the aqueous pharmaceutical composition. The lyophilized solid is described as a solid composition that reconstitutes into the same aqueous pharmaceutical composition upon mixing with water. The overall disclosure connects the defined composition components and concentrations to stability and performance under stress conditions, and supports subcutaneous administration at constrained dosing volume and concentration considerations for exemplary antibodies such as AM001.

Claims Coverage

The patent includes three independent claims. Across these independent claims, the inventive subject matter centers on an aqueous high-concentration antibody formulation with specific heavy- and light-chain sequences (SEQ ID NO:7 and SEQ ID NO:8) combined with defined arginine salt, histidine, polysorbate, and a controlled acidic pH, including additional “consisting essentially of” limitations and a lyophilized solid alternative.

High-concentration acidic aqueous antibody formulation with arginine salt, histidine, and polysorbate

An aqueous pharmaceutical composition comprising 105 to 250 mg/mL of an antibody having a heavy chain comprising SEQ ID NO:7 and a light chain comprising SEQ ID NO:8, a salt of arginine selected from arginine glutamate, arginine aspartate, and arginine HCl, histidine, and polysorbate selected from PS 80 and PS 20 at a pH of 5.4-5.6.

Consisting essentially of formulation of arginine salt, histidine, and polysorbate at pH 5.4-5.6

An aqueous pharmaceutical composition, consisting essentially of 105 to 250 mg/mL of an antibody, 100 mM to 200 mM of arginine glutamate, arginine aspartate, or arginine HCl, 10 mM to 50 mM histidine, and 0.015 to 0.035 w/v % of polysorbate, at a pH of 5.4 to 5.6, wherein the antibody comprises a heavy chain comprising SEQ ID NO:7 and a light chain comprising SEQ ID NO:8.

Defined high-concentration aqueous antibody composition with specified concentrations and acidic pH

An aqueous pharmaceutical composition, consisting of 105 to 250 mg/mL of an antibody, 100 mM to 200 mM of arginine glutamate, arginine aspartate, or arginine HCl, 10 mM to 50 mM histidine, and 0.015 to 0.035 w/v % of polysorbate, at a pH of 5.4 to 5.6, wherein the antibody comprises a heavy chain comprising SEQ ID NO:7 and a light chain comprising SEQ ID NO:8.

All independent claims require an aqueous pharmaceutical composition containing a specified anti-CSF1R/CSF1 antibody defined by SEQ ID NO:7 (heavy chain) and SEQ ID NO:8 (light chain), formulated at high antibody concentration (105 to 250 mg/mL) with selected arginine salts, histidine, and polysorbate at pH 5.4 to 5.6. One independent claim further limits the formulation to “consisting essentially of” specified component ranges, and dependent claims add specific exclusions of other excipients and provide a lyophilized solid option.

Stated Advantages

Improves stability at high concentration by maintaining favorable stability in a narrow acidic pH window.

Controls viscosity at high concentration via identification of histidine and arginine salts as key components for low viscosity.

Reduces problems associated with high concentration formulations, including turbidity/opalescence, protein aggregation, phase separation, and deamidation.

Documented Applications

Treatment of tenosynovial giant cell tumor (TGCT) using local administration, with subcutaneous administration described for the disclosed formulations.

Treatment of idiopathic pulmonary fibrosis (IPF).

Treatment of polycystic kidney disease (PKD).

Treatment of ocular diseases.

Treatment of other tumors, including melanoma, glioblastoma, and leukemia.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.